Skip to main content
Premium Trial:

Request an Annual Quote

Cellecta DriverMap RNA-Seq Panels, Analysis Software

Cellecta has launched five DriverMap Predesigned RNA-Seq panels, including the Human Cell Marker Panel, Human Hallmark Signatures Panel, Human LINCSx Panel, Human Pan-Cancer Pathway Panel, and the Human Transcription Factor Signature Panel. Each panel measures expression levels of over 1,200 curated essential genes selected from publications, open access databases, and other resources. The panels use the same multiplex RT-PCR followed by next-generation sequencing approach as the firm's DriverMap Expression Profiling assay, which measures expression levels of all protein-coding human genes.

The kits include a complete set of gene-specific and PCR-NGS primers, buffers, spiked-in EERC and positive control RNAs, as well as all necessary reagents required to profile 96 samples and prepare them for digital expression profiling on a Illumina sequencing platform also come with genome alignment software that provides differential expression data in an excel spreadsheet format. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.